# Illimis Therapeutics

> Illimis Therapeutics is a Seoul-based biotechnology company developing protein-based medicines for central nervous system and immune diseases. Its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform builds bispecific fusion proteins that engage the body's TAM receptors to clear misfolded proteins such as amyloid-beta through phagocytosis without triggering the inflammation and ARIA side effects associated with existing antibody drugs. Founded in 2021, the company raised a $42 million Series B in July 2025 and is advancing a lead Alzheimer's candidate, ILM01, toward an IND by the end of 2027.

- **Founded:** 2021
- **Headquarters:** Seoul, South Korea
- **Founders:** Sanghoon Park (Co-Founder & CEO), Chanhyeok Kim (Co-Founder), Jeong Won Seok (Co-Founder)
- **Team size:** ~25 employees
- **Products:** GAIA Platform, ILM01, ILM02, ILM03
- **Notable:** Closed $42M (58B KRW) Series B in July 2025 with 18 total investors, Signed a collaboration with Eli Lilly's Catalyze360-ExploR&D in October 2024, Preclinical data showed better cognitive improvement and markedly reduced ARIA versus aducanumab

## Products & services

- **GAIA Platform** — Gas6-mediated Anti-Inflammatory Adaptor platform. A bispecific fusion protein technology that mounts a disease-target binder (e.g. amyloid) on one arm and an engineered Gas6 (the soluble ligand of TAM receptors) on the other. It dimerizes TAM receptors to trigger phagocytic clearance of misfolded proteins via efferocytosis - removing pathology without inducing inflammation.
- **ILM01** — Lead candidate targeting amyloid-beta for Alzheimer's disease. Entered preclinical stage in H2 2025 with IND submission targeted by end of 2027. In preclinical studies it showed better cognitive improvement and markedly reduced ARIA side effects versus aducanumab.
- **ILM02** — Pipeline candidate targeting tau for neurodegenerative disease.
- **ILM03** — Pipeline candidate targeting alpha-synuclein (relevant to Parkinson's and related synucleinopathies).

## Achievements

- Closed $42M (58B KRW) Series B in July 2025 with 18 total investors
- Signed a collaboration with Eli Lilly's Catalyze360-ExploR&D in October 2024
- Preclinical data showed better cognitive improvement and markedly reduced ARIA versus aducanumab
- Selected for the 2025 Global Joint Research to Defeat Dementia program
- Winner, BMS Innovation Square Challenge (2023)
- Presented GAIA data at AAIC 2025 and BIO International Convention 2025
- Peer-reviewed publication in Alzheimer's & Dementia (2025)

## Latest updates

- **2025-07** — Closed $42M Series B financing to accelerate CNS and immune disease drug development via the GAIA platform.
- **2025-07** — Presented GAIA / GAS6 fusion protein efferocytosis data at AAIC 2025; peer-reviewed paper published in Alzheimer's & Dementia.
- **2025-06** — Exhibited at BIO International Convention 2025.
- **2024-10** — Announced collaboration with Eli Lilly's Catalyze360-ExploR&D on neurodegenerative disease.

## Links

- Website: https://illimistx.com
- LinkedIn: https://www.linkedin.com/company/illimis-therapeutics
- Twitter/X: https://twitter.com/Illimistx
- YouTube: https://www.youtube.com/channel/UC3tRHPdwDnYWLu6AFsxyyUw

---

Profile page: https://yespress.io/illimis-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-20